Literature DB >> 23696595

Decreased expression of microRNA-206 in breast cancer and its association with disease characteristics and patient survival.

Yuyang Li1, Fanzhen Hong, Zhigang Yu.   

Abstract

OBJECTIVES: MicroRNA-206 (miR-206) is downregulated in many human malignancies, which correlates with tumour progression. This study characterized the contribution of miR-206 to the initiation and progression of human breast cancer.
METHODS: Consecutive primary breast cancer patients who received radical resection were enrolled. Breast cancer tissue samples were obtained during surgery. MiR-206 levels in matched pairs of cancer tissue and normal adjacent tissue (NAT) samples were examined using quantitative reverse transcription-polymerase chain reaction. The relationship between miR-206 levels and clinicopathological characteristics and overall survival was also investigated.
RESULTS: In 128 patients with breast cancer, miR-206 was downregulated in 119 (93%) tumour tissue compared with their matched NAT samples. Decreased miR-206 was significantly associated with advanced clinical stage and lymph node metastasis. Univariate and multivariate Cox proportional hazard regression analysis revealed that a low miR-206 level was an unfavourable prognostic factor for overall survival, in patients with breast cancer.
CONCLUSIONS: This study indicated that miR-206 may be a good candidate as a novel prognostic indicator in breast cancer patients.

Entities:  

Keywords:  MicroRNA-206 (miR-206); breast cancer; metastasis; prognosis; tumour stage

Mesh:

Substances:

Year:  2013        PMID: 23696595     DOI: 10.1177/0300060513485856

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  27 in total

1.  Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma.

Authors:  Rong Tian; Tao Liu; Li Qiao; Mei Gao; Jing Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma.

Authors:  Chun Zhang; Cong Yao; Haopeng Li; Guoyu Wang; Xijing He
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  MicroRNA-206 inhibits the viability and migration of medulloblastoma cells by targeting LIM and SH3 protein 1.

Authors:  Xuexia Pan; Zhimin Wang; Bin Wan; Zhenwen Zheng
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

4.  miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer.

Authors:  Jun Wang; Efrosini Tsouko; Philip Jonsson; Jonas Bergh; Johan Hartman; Eylem Aydogdu; Cecilia Williams
Journal:  Mol Oncol       Date:  2014-07-12       Impact factor: 6.603

5.  Downregulation of microRNA-206 promotes invasion and angiogenesis of triple negative breast cancer.

Authors:  Zhongxing Liang; Xuehai Bian; Hyunsuk Shim
Journal:  Biochem Biophys Res Commun       Date:  2016-06-16       Impact factor: 3.575

6.  Reduced expression of microRNA‑206 regulates cell proliferation via cyclinD2 in gliomas.

Authors:  Xue Yang; Chuanbao Zhang; Tianzhu Guo; Ying Feng; Qingyang Liu; Yan Chen; Quangeng Zhang
Journal:  Mol Med Rep       Date:  2015-01-09       Impact factor: 2.952

Review 7.  Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management.

Authors:  Eleni van Schooneveld; Hans Wildiers; Ignace Vergote; Peter B Vermeulen; Luc Y Dirix; Steven J Van Laere
Journal:  Breast Cancer Res       Date:  2015-02-18       Impact factor: 6.466

Review 8.  MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer.

Authors:  Gloria Bertoli; Claudia Cava; Isabella Castiglioni
Journal:  Theranostics       Date:  2015-07-13       Impact factor: 11.556

Review 9.  Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients.

Authors:  Véronique C LeBlanc; Pier Morin
Journal:  J Clin Med       Date:  2015-08-14       Impact factor: 4.241

Review 10.  MicroRNA-206: a promising theranostic marker.

Authors:  Jan Novák; Peter Kružliak; Julie Bienertová-Vašků; Ondřej Slabý; Miroslav Novák
Journal:  Theranostics       Date:  2014-01-02       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.